CClinicalTrials.gg
CompletedNCT05064046Updated Aug 5, 2022

Educating Providers About Lung Screening

An interventional study of LuCa + Health Disparity module in Lung Cancer, sponsored by Georgetown University. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by Georgetown University · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
77
Allocation
Randomized
Sex
All
01

Study summary

We are conducting a randomized trial to compare the Health Disparities module to an existing provider module on lung cancer screening to evaluate the impact on primary care providers' knowledge, attitudes, and lung cancer screening referrals of African American and White patients.

Read the detailed description

We are conducting a randomized trial of two online, provider-facing education modules regarding lung cancer screening and smoking cessation. We will accrue 70 MedStar primary care providers (PCP). The baseline survey will incorporate items regarding lung cancer screening knowledge, providers' attitudes towards lung cancer screening, lung cancer screening ordering practices and provider characteristics. At the end of the baseline survey, PCPs will be randomly assigned to the LuCa + Health Disparities or LuCa only. PCPs will be asked to complete the intervention and the post-test within 1 week of randomization. The post test will cover knowledge of lung cancer screening, attitudes and opinions toward LCS. To assess PCP lung cancer screening ordering practices, we will review the MedConnect Electronic Health Record (EHR) to compare the two study groups post-randomization on the number of orders made for LCS.

02

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • lung cancer screening
  • provider education
  • health disparities
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 77 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Georgetown University is the lead sponsor of 286 studies on the registry; 42 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 20 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • MedStar provider (attending or resident physician, physician's assistant, or nurse practitioner)
  • English speaking
  • ability to provide meaningful consent
  • ability to provide last two digits of NPI.

Exclusion criteria

Exclusion Criteria:

  • N/A
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Single group
Masking
Single (Investigator)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    LuCa + Health Disparity module

    Participants will be asked to complete the Health Disparities module that is an interactive CME/CE online course which offers 0.5 continuing education credit hours. The will also be asked to complete the LuCa course.

    Behavioral: LuCa + Health Disparity module

  • Active comparator
    LuCa only module

    LuCa is a free interactive CME/CE online course entitled, "Lung Cancer and the Primary Care Provider". For the purpose of this study, participants will be asked to complete session 1 which offers 1.0 continuing education credit hours, including AMA PRA Category 1 credits, AANP, and AAFP Prescribed credits.

    Behavioral: LuCa + Health Disparity module

Interventions

  • BehavioralLuCa + Health Disparity module

    The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance. Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making.

06

What researchers measure

Primary outcomes

  1. Number of providers with improved mean lung cancer screening knowledge score

    Knowledge about lung cancer screening

    Time frame: 1 week

  2. Number of providers with improved mean attitudes score

    Attitudes about lung cancer screening

    Time frame: 1 week

Secondary outcomes

  1. Rate of lung cancer screening referrals

    Lung cancer screening referrals from the electronic health record

    Time frame: 2 months post-randomization

07

Study locations

1 site
  • MedStar Health Georgetown University Hospital
    Washington, District of Columbia 20007, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05064046
Lead sponsor
Georgetown University
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Oct 27, 2021
Primary completion
Feb 28, 2022
Completion
Jul 27, 2022
Last update
Aug 5, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion